Double-blind, randomised controlled trials (RCTs) of the acute treatment of schizophrenia with fixed doses of quetiapine were eligible for inclusion. Trials of patients with schizoaffective disorder, and trials of 50mg/day (which was deemed sub-therapeutic) were excluded.
In the included trials, low doses ranged from 300 to 400mg/day, and high doses from 750 to 800mg/day. One trial was of in-patients only; the other trial excluded hospitalised patients.
Response rates, discontinuation rates, and changes in symptoms scores were the main outcomes of interest. Studies used different scales to measure outcomes.
It appeared that one reviewer selected studies.